Yi Zhang1, Xiao-Ya Guan, Bin Dong, Min Zhao, Jian-Hui Wu, Xiu-Yun Tian, Chun-Yi Hao. 1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Hepato-Pancreato-Biliary Surgery, Peking University School of Oncology, Peking University Cancer Hospital and Institute, 52 Fucheng Rd, Haidian District, Beijing, 100142, China.
Abstract
PURPOSE: To investigate matrix metalloproteinase 9 (MMP-9) and WAVE3 expression in human colorectal cancer (CRC) and to evaluate their clinical significance. METHODS: We first performed real-time PCR to evaluate mRNA expression of MMP-9 and WAVE3 in 21 pairs of fresh CRC samples matched with adjacent normal mucosa. Then, MMP-9 and WAVE3 proteins were evaluated by immunohistochemistry on CRC tissue microarrays which included 216 CRC specimens and corresponding normal colorectal mucosa, and their correlation with clinicopathological factors and overall survival after surgery was evaluated. RESULTS: Both real-time PCR and immunohistochemistry evaluation have demonstrated that MMP-9 and WAVE3 were over-expressed in colorectal cancer tissues compared with normal mucosa (p < 0.001). MMP-9 expression was significantly higher in patients with low-grade differentiation and distant metastasis (p = 0.003 and p = 0.005, respectively), and patients with MMP-9-positive expression had a poorer prognosis (p = 0.008). However, patients with WAVE3-positive expression had a better prognosis (p = 0.039) and particularly favorable prognostic factors, including non-lymph node metastasis, non-distant metastasis, and early TNM stage (p = 0.029, 0.021, and 0.003, respectively). In addition, MMP-9-negative/WAVE3-positive patients had the best overall survival (p = 0.021). In multivariate survival analysis, MMP-9 expression and combined expression status of MMP-9/WAVE3 were identified as independent prognostic factors for CRC (p = 0.046 and p = 0.019, respectively). CONCLUSIONS: Combined analysis of MMP-9 and WAVE3 has a significant value for assessing prognosis of CRC patients after surgery.
PURPOSE: To investigate matrix metalloproteinase 9 (MMP-9) and WAVE3 expression in humancolorectal cancer (CRC) and to evaluate their clinical significance. METHODS: We first performed real-time PCR to evaluate mRNA expression of MMP-9 and WAVE3 in 21 pairs of fresh CRC samples matched with adjacent normal mucosa. Then, MMP-9 and WAVE3 proteins were evaluated by immunohistochemistry on CRC tissue microarrays which included 216 CRC specimens and corresponding normal colorectal mucosa, and their correlation with clinicopathological factors and overall survival after surgery was evaluated. RESULTS: Both real-time PCR and immunohistochemistry evaluation have demonstrated that MMP-9 and WAVE3 were over-expressed in colorectal cancer tissues compared with normal mucosa (p < 0.001). MMP-9 expression was significantly higher in patients with low-grade differentiation and distant metastasis (p = 0.003 and p = 0.005, respectively), and patients with MMP-9-positive expression had a poorer prognosis (p = 0.008). However, patients with WAVE3-positive expression had a better prognosis (p = 0.039) and particularly favorable prognostic factors, including non-lymph node metastasis, non-distant metastasis, and early TNM stage (p = 0.029, 0.021, and 0.003, respectively). In addition, MMP-9-negative/WAVE3-positive patients had the best overall survival (p = 0.021). In multivariate survival analysis, MMP-9 expression and combined expression status of MMP-9/WAVE3 were identified as independent prognostic factors for CRC (p = 0.046 and p = 0.019, respectively). CONCLUSIONS: Combined analysis of MMP-9 and WAVE3 has a significant value for assessing prognosis of CRC patients after surgery.
Authors: Felix B Engel; Michael Schebesta; Mychelle T Duong; Gang Lu; Shuxun Ren; Jeffery B Madwed; Huiping Jiang; Yibin Wang; Mark T Keating Journal: Genes Dev Date: 2005-05-03 Impact factor: 11.361
Authors: R J Lee; C Albanese; R J Stenger; G Watanabe; G Inghirami; G K Haines; M Webster; W J Muller; J S Brugge; R J Davis; R G Pestell Journal: J Biol Chem Date: 1999-03-12 Impact factor: 5.157
Authors: Weigang Wang; Sumanta Goswami; Kyle Lapidus; Amber L Wells; Jeffrey B Wyckoff; Erik Sahai; Robert H Singer; Jeffrey E Segall; John S Condeelis Journal: Cancer Res Date: 2004-12-01 Impact factor: 12.701
Authors: Riyad Bendardaf; Abdelbaset Buhmeida; Marja Hilska; Matti Laato; Stina Syrjänen; Kari Syrjänen; Yrjö Collan; Seppo Pyrhönen Journal: Cancer Invest Date: 2010-01 Impact factor: 2.176
Authors: Viktor A Adalsteinsson; Narmin Tahirova; Naren Tallapragada; Xiaosai Yao; Liam Campion; Alessandro Angelini; Thomas B Douce; Cindy Huang; Brittany Bowman; Christina A Williamson; Douglas S Kwon; K Dane Wittrup; J Christopher Love Journal: Integr Biol (Camb) Date: 2013-10 Impact factor: 2.192
Authors: Christopher J Hayes; Catriona M Dowling; Susan Dwane; Mary E McCumiskey; Shona M Tormey; B Anne Merrigan; John C Coffey; Patrick A Kiely; Tara M Dalton Journal: Biomicrofluidics Date: 2016-10-31 Impact factor: 2.800
Authors: Gangarao Davuluri; Katarzyna Augoff; William P Schiemann; Edward F Plow; Khalid Sossey-Alaoui Journal: PLoS One Date: 2014-10-16 Impact factor: 3.240
Authors: T Kantola; J P Väyrynen; K Klintrup; J Mäkelä; S M Karppinen; T Pihlajaniemi; H Autio-Harmainen; T J Karttunen; M J Mäkinen; A Tuomisto Journal: Br J Cancer Date: 2014-08-19 Impact factor: 7.640